Borneo vs Bali Kratom: What the Labels Mean and What Lab Data Shows

Borneo and Bali kratom are the same plant, Mitragyna speciosa, sold under different place names. “Borneo” refers to a large island shared by Indonesia, Malaysia and Brunei; “Bali” is widely used as a trade name, and sellers themselves often say the leaf is grown elsewhere. No controlled study shows that one reliably differs from the other in alkaloids or effects.

That is not the impression most vendor pages give. Search results for this comparison are dominated by sellers, who describe distinct personalities for each name and for each vein colour within it, usually without data.

This page looks at what the labels can and cannot tell you, what independent laboratory analyses have found, and why a batch certificate of analysis says more about a product than its name. It gives no dosing advice and does not recommend either label.

At a glance

Property	Borneo kratom	Bali kratom
What the name refers to	An island shared by Indonesia, Malaysia and Brunei	An Indonesian island; widely used as a trade name
Species	Mitragyna speciosa	Mitragyna speciosa (same species)
Origin verifiable from label?	Rarely; no certification scheme exists	Rarely; sellers often say it is grown elsewhere
Vein colours sold	Red, green, white	Red, green, white
Main alkaloid	Mitragynine	Mitragynine
Direct lab comparison	None published for Borneo vs Bali	Bali products matched others in one vendor analysis
Seller effect descriptions	Vary between vendors	Vary between vendors
Controlled human studies	None	None
Best guide to content	Batch certificate of analysis	Batch certificate of analysis

What “Borneo” and “Bali” mean on a kratom label

Kratom product names usually combine a place and a vein colour: Red Borneo, Green Bali, White Borneo and so on. The place part is meant to signal where the leaf was grown. The colour part refers to the colour of the leaf’s central vein or, in practice, to how the leaf was dried and processed. Our guide to kratom strains explains the naming system in more depth.

Borneo is the third-largest island in the world, split between Indonesian Kalimantan, the Malaysian states of Sabah and Sarawak, and Brunei. A “Borneo” label therefore covers a huge area and several countries, and on its own says little about a specific farm or growing condition. See our glossary entry on Borneo kratom.

Bali is a small Indonesian island best known for tourism. Several of the sellers ranking for this comparison describe “Bali” as a commercial name for leaf grown elsewhere in Indonesia, often on Borneo, and shipped through Bali. We found no independent documentation either confirming or ruling that out, which is itself the point: origin claims on kratom labels are not verified by any certification scheme. Our Bali kratom glossary entry has more.

What laboratory analyses actually show

No published study has compared products labelled Borneo with products labelled Bali head to head. Several studies do show how much, and how little, product names track chemistry.

• Product names did not predict alkaloids. A 2023 study had six products from one vendor analysed, including Green Bali and Red Bali alongside Maeng Da and Thai products. There were no significant differences in mitragynine, paynantheine, speciogynine or speciociliatine between them¹.
• Vein colour did not predict alkaloids either. A 2026 study of eight Thai kratom accessions with visibly different vein colours found alkaloid profiles in mature leaves were largely consistent across all of them; leaf age mattered more².
• Commercial products are qualitatively similar but quantitatively variable. An analysis of US products found the same set of 12 to 13 alkaloids in each, dominated by mitragynine, with the other major alkaloids varying from product to product³.
• Growing conditions and processing matter. Mitragynine content in wild Thai kratom varied more than threefold between sites, linked to light, humidity and soil⁵. Withering time, drying temperature, cultivar and season all shifted alkaloid levels in a 2025 study⁶.

One study complicates the picture. Researchers measured 13 elements in 19 samples from a single online distributor and could classify them by purported country of origin and product line with high accuracy⁴. That suggests products sold under different names can differ in trace minerals, but it says nothing about alkaloids or effects, and the origins were the seller’s own claims.

Put together, the evidence suggests that batch-to-batch variation from harvest, drying and storage is likely to be at least as large as any systematic difference between a Borneo and a Bali label.

How the reported effects compare

Seller descriptions of Borneo and Bali kratom vary from shop to shop, and the same label can be described as relaxing by one vendor and balanced by another. Most attribute differences mainly to vein colour rather than to the place name, with red labels described as calming and white labels as energising.

The 2023 study is useful here because it paired chemistry with experience. Its 644 survey respondents, mostly customers of the analysed vendor, reported effects that matched common marketing descriptions for each colour, even though the products did not differ significantly in measured alkaloids¹. The authors suggested that perceived differences may be disproportionately shaped by marketing and anecdote, and called for blinded experiments.

That does not prove every perceived difference is expectation. Minor alkaloids and other compounds were not fully examined, and one vendor’s products are a small sample. But it does mean the honest answer to “how do Borneo and Bali kratom differ?” is that no one has shown they reliably do.

Whatever the label, kratom’s main alkaloid mitragynine is a partial agonist at the mu-opioid receptor⁷, and the broad pattern of effects users describe is dose-dependent rather than name-dependent.

Evidence quality: what is known and what is not

The research base on kratom strain names is thin and mostly indirect.

• No controlled human studies compare Borneo and Bali kratom, or any two named strains, for effects.
• Chemistry studies are small. The vendor analysis covered six products¹; the Thai accession study covered eight trees²; the elemental study used 19 samples from one seller⁴.
• Origin is unverified. Studies of commercial products rely on what the seller says about where the leaf came from.
• Surveys measure belief as well as effect. When users know what they are taking, expectations shaped by product descriptions can colour what they report.

Seller pages that state precise alkaloid percentages for “Bali” or “Borneo” as a category, rather than for a tested batch, are going beyond what the evidence supports.

Safety, interactions and drug testing

Because Borneo and Bali are labels on the same plant, the safety considerations are the same for both.

• Dependence and withdrawal. In a survey of 293 regular users in Malaysia, more than half met criteria for severe dependence, and withdrawal symptoms included muscle aches, sleep problems and irritability⁸. See our entry on kratom withdrawal.
• Liver injury. Rare, but a 2020 review applying formal causality assessment concluded kratom likely causes liver injury, based on low-quality human evidence alongside animal and mechanistic data⁹.
• Drug interactions. Kratom modestly raised blood levels of midazolam, a drug cleared by CYP3A, in a controlled human study¹¹. Our guide to kratom and drug interactions covers which medicines are affected.
• Drug tests. Standard workplace panels do not target kratom, but specific mitragynine tests exist, and the strain name makes no difference.

A product sold as “extra strength” or “enhanced” Bali or Borneo is a different matter from leaf powder. Concentrated or 7-OH-enriched products carry more risk than plain leaf, whatever place name they use.

Legal status as of September 2026

The place name on a kratom product has no legal significance. What matters is where you are and what the product contains.

US federal: kratom leaf is not a controlled substance. In July 2026 the DEA gave notice that it intends to temporarily place 7-hydroxymitragynine in Schedule I above 0.050% of dry weight in botanical material, or above set limits in processed products; botanical kratom below that threshold is excluded¹⁰. At the time of writing, that order had not yet been published. Mitragynine pseudoindoxyl, MGM-15 and MGM-16 were temporarily scheduled from 26 August 2026.

US states: several states and some localities ban kratom outright, and many others regulate it through Kratom Consumer Protection Acts with age limits and labelling requirements. See our state-by-state guide.

UK: kratom is covered by the Psychoactive Substances Act 2016, so supplying it for human consumption is an offence. Canada: Health Canada has not authorised kratom for ingestion and has seized products marketed that way.

What to check instead of the strain name

If the name is a weak guide, the batch certificate of analysis (COA) is a better one. Our guide on how to read a kratom COA walks through a real report.

1. A batch number that matches the product. A generic “Bali” COA reused across batches tells you nothing about the pouch in your hand.
2. Mitragynine and 7-OH reported separately, as a percentage, from an independent laboratory. Natural leaf contains very little 7-OH; in one 2025 study, it made up only 0.02 to 0.04% of leaf alkaloid extracts and was not detected in every season⁶.
3. Heavy metals and microbial testing, since contamination risks do not depend on the strain name.
4. No disease claims. Labels promising pain relief, anxiety relief or opioid withdrawal help are making drug claims and are a warning sign.

Our list of kratom COA red flags covers common problems, including reports that do not match the product or lab.

Frequently asked questions

Is Bali kratom actually from Bali?

Often not, according to sellers themselves. Several vendors describe Bali as a trade name for leaf grown elsewhere in Indonesia, frequently on Borneo, and shipped through Bali. There is no certification scheme for kratom origin, so a Bali or Borneo label cannot be independently verified. A batch lab report is more informative than the place name.

Which is stronger, Borneo or Bali kratom?

There is no evidence that either label is consistently stronger. In one vendor analysis, Bali products did not differ significantly in alkaloid content from other named strains¹, and alkaloid levels vary with growing conditions, drying and season⁵⁶. Strength depends on the batch, which is why the mitragynine figure on a certificate of analysis matters more than the name.

What is the difference between Red Borneo and Red Bali?

Both are red-labelled Mitragyna speciosa sold under different place names. Sellers describe them differently, but no published study has compared them directly. The closest evidence, a 2023 analysis that included Red Bali, found no significant alkaloid differences between differently named products from the same vendor¹. Batch testing is the only way to know how two products compare.

Does vein colour change kratom’s effects?

Users report that it does, but the chemistry is less clear. A 2026 study of Thai kratom trees with visibly different vein colours found alkaloid profiles in mature leaves were largely consistent across them². Many commercial colour labels are thought to reflect drying and processing rather than the living leaf, and no blinded human study has tested colour effects.

Is Borneo or Bali kratom legal?

Legality depends on kratom law where you are, not on the strain name. Kratom leaf is not federally scheduled in the US, though some states and cities ban it and the DEA is moving against concentrated 7-OH products¹⁰. Supplying kratom for human consumption is an offence in the UK, and Canada has not authorised it for ingestion.

Sources

1. Huisman G, Menke M, Grundmann O, Schreiber R, Mason N. Examining the Psychoactive Differences between Kratom Strains. Int J Environ Res Public Health. 2023;20(14):6425. DOI: 10.3390/ijerph20146425. PMID: 37510657. pubmed.ncbi.nlm.nih.gov
2. Ransden KE, Ramachandria P, Laforest LC, et al. Comparative analysis of monoterpene indole alkaloid composition and genotypic variation in Thai Mitragyna speciosa. Front Plant Sci. 2026;17:1821609. DOI: 10.3389/fpls.2026.1821609. PMID: 42158609. pubmed.ncbi.nlm.nih.gov
3. Manwill PK, Flores-Bocanegra L, Khin M, et al. Kratom (Mitragyna speciosa) Validation: Quantitative Analysis of Indole and Oxindole Alkaloids Reveals Chemotypes of Plants and Products. Planta Med. 2022;88(9-10):838-857. DOI: 10.1055/a-1795-5876. PMID: 35468648. pubmed.ncbi.nlm.nih.gov
4. Braley C, Hondrogiannis EM. Differentiation of Commercially Available Kratom by Purported Country of Origin using Inductively Coupled Plasma-Mass Spectrometry. J Forensic Sci. 2020;65(2):428-437. DOI: 10.1111/1556-4029.14201. PMID: 31560807. pubmed.ncbi.nlm.nih.gov
5. Leksungnoen N, Andriyas T, Ngernsaengsaruay C, et al. Variations in mitragynine content in the naturally growing Kratom (Mitragyna speciosa) population of Thailand. Front Plant Sci. 2022;13:1028547. DOI: 10.3389/fpls.2022.1028547. PMID: 36388525. pubmed.ncbi.nlm.nih.gov
6. Zhang M, Lyndon A, Kanumuri SRR, et al. Alkaloid biosynthesis in medicinal crop kratom (Mitragyna speciosa) varies with postharvest, genetic, and seasonal factors. Front Plant Sci. 2025;16:1653916. DOI: 10.3389/fpls.2025.1653916. PMID: 41090093. pubmed.ncbi.nlm.nih.gov
7. Kruegel AC, Gassaway MM, Kapoor A, et al. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. J Am Chem Soc. 2016;138(21):6754-6764. DOI: 10.1021/jacs.6b00360. PMID: 27192616. pubmed.ncbi.nlm.nih.gov
8. Singh D, Müller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014;139:132-137. DOI: 10.1016/j.drugalcdep.2014.03.017. PMID: 24698080. pubmed.ncbi.nlm.nih.gov
9. Schimmel J, Dart RC. Kratom (Mitragyna Speciosa) Liver Injury: A Comprehensive Review. Drugs. 2020;80(3):263-283. DOI: 10.1007/s40265-019-01242-6. PMID: 31919755. pubmed.ncbi.nlm.nih.gov
10. Drug Enforcement Administration. Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I (notice of intent). Federal Register. 6 July 2026. Document 2026-13580. federalregister.gov
11. Tanna RS, Nguyen JT, Hadi DL, et al. Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom. Clin Pharmacol Ther. 2023;113(6):1315-1325. DOI: 10.1002/cpt.2891. PMID: 36924284. pubmed.ncbi.nlm.nih.gov

Editorial note: This article is for general information only and is not medical or legal advice. Kratom products have not been evaluated by the FDA to diagnose, treat, cure or prevent any disease. Laws vary by location and change often, so verify the rules that apply where you are. Always talk to a licensed healthcare provider before use, especially if you are under 21, pregnant or nursing, taking medication, or managing a health condition.